For instance, DHEA-S is a depot for local androgen synthesis in prostate cancer patients also after hormone therapy using 17a-hydroxylase-17,20-lyase (CYP17A1) inhibitors (Penning, 2018), and STS inhibitors demonstrated useful for the treatment of prostate cancer resistant to anti-androgen drugs (Armstrong et al., 2020). This evidence concerns the gene CYP17A1 and prostate cancer.